Q32 Bio (QTTB) Competitors $2.57 +0.14 (+5.76%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.57 +0.00 (+0.16%) As of 02/21/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends QTTB vs. ADAP, CDTX, IFRX, LXEO, BTAI, STRO, NKTX, SLN, ZNTL, and FATEShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Adaptimmune Therapeutics (ADAP), Cidara Therapeutics (CDTX), InflaRx (IFRX), Lexeo Therapeutics (LXEO), BioXcel Therapeutics (BTAI), Sutro Biopharma (STRO), Nkarta (NKTX), Silence Therapeutics (SLN), Zentalis Pharmaceuticals (ZNTL), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Adaptimmune Therapeutics Cidara Therapeutics InflaRx Lexeo Therapeutics BioXcel Therapeutics Sutro Biopharma Nkarta Silence Therapeutics Zentalis Pharmaceuticals Fate Therapeutics Q32 Bio (NASDAQ:QTTB) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Which has more risk & volatility, QTTB or ADAP? Q32 Bio has a beta of -0.32, indicating that its stock price is 132% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500. Which has better earnings & valuation, QTTB or ADAP? Q32 Bio has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M26.99-$112.96M-$14.25-0.18Adaptimmune Therapeutics$60.28M2.37-$113.87M-$0.22-2.54 Is QTTB or ADAP more profitable? Q32 Bio has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Adaptimmune Therapeutics' return on equity of -74.15% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -146.18% -54.49% Adaptimmune Therapeutics -25.43%-74.15%-15.09% Do institutionals & insiders have more ownership in QTTB or ADAP? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor QTTB or ADAP? Adaptimmune Therapeutics received 305 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 66.67% of users gave Q32 Bio an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformQ32 BioOutperform Votes1266.67% Underperform Votes633.33% Adaptimmune TherapeuticsOutperform Votes31763.02% Underperform Votes18636.98% Do analysts rate QTTB or ADAP? Q32 Bio presently has a consensus price target of $24.86, suggesting a potential upside of 867.20%. Adaptimmune Therapeutics has a consensus price target of $2.79, suggesting a potential upside of 398.21%. Given Q32 Bio's higher probable upside, analysts plainly believe Q32 Bio is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor QTTB or ADAP? In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Q32 Bio. MarketBeat recorded 1 mentions for Adaptimmune Therapeutics and 0 mentions for Q32 Bio. Adaptimmune Therapeutics' average media sentiment score of 1.22 beat Q32 Bio's score of 0.79 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Q32 Bio Positive Adaptimmune Therapeutics Positive SummaryAdaptimmune Therapeutics beats Q32 Bio on 11 of the 17 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.60M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / Sales26.99281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book0.116.717.644.65Net Income-$112.96M$138.11M$3.18B$245.69M7 Day Performance-3.75%-2.54%-1.95%-2.68%1 Month Performance-25.29%-2.00%-0.23%-2.16%1 Year PerformanceN/A-5.04%16.69%12.90% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.9948 of 5 stars$2.57+5.8%$24.86+867.2%N/A$29.60M$1.16M0.0039ADAPAdaptimmune Therapeutics2.3358 of 5 stars$0.60-3.1%$2.79+363.8%-62.7%$153.79M$175.04M-2.73490Positive NewsCDTXCidara Therapeutics3.9205 of 5 stars$21.73+0.2%$32.20+48.2%+55.6%$153.13M$44.65M-0.8590IFRXInflaRx3.2978 of 5 stars$2.60+5.3%$8.00+207.7%+21.9%$153.09M$70,000.00-2.4160Gap DownLXEOLexeo Therapeutics3.3573 of 5 stars$4.62-6.7%$23.80+415.2%-74.8%$152.78M$650,000.00-1.4658News CoverageGap UpBTAIBioXcel Therapeutics4.0924 of 5 stars$2.98+12.9%$37.00+1,141.6%-95.8%$147.90M$1.38M-1.3890STROSutro Biopharma4.2576 of 5 stars$1.79-10.1%$11.13+521.5%-61.9%$147.60M$153.73M-1.11240High Trading VolumeNKTXNkarta2.6168 of 5 stars$2.09-3.7%$15.00+617.7%-78.5%$147.49MN/A-1.11140SLNSilence Therapeutics2.4547 of 5 stars$4.92-1.8%$54.75+1,012.8%-79.9%$147.26M$31.55M-3.13100ZNTLZentalis Pharmaceuticals1.917 of 5 stars$2.06+7.3%$8.24+300.2%-83.0%$146.80MN/A-0.83160Gap UpFATEFate Therapeutics4.203 of 5 stars$1.25-1.6%$6.75+440.0%-79.2%$142.36M$63.53M-0.76550 Related Companies and Tools Related Companies Adaptimmune Therapeutics Competitors Cidara Therapeutics Competitors InflaRx Competitors Lexeo Therapeutics Competitors BioXcel Therapeutics Competitors Sutro Biopharma Competitors Nkarta Competitors Silence Therapeutics Competitors Zentalis Pharmaceuticals Competitors Fate Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QTTB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QTTB Stock Alerts